3,903 Shares in Stryker Corporation $SYK Acquired by Fairtree Asset Management Pty Ltd

Fairtree Asset Management Pty Ltd purchased a new position in Stryker Corporation (NYSE:SYK) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 3,903 shares of the medical technology company’s stock, valued at approximately $1,372,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Czech National Bank lifted its position in shares of Stryker by 3.9% during the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after buying an additional 3,366 shares in the last quarter. Davis R M Inc. lifted its position in shares of Stryker by 1.8% during the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after buying an additional 2,512 shares in the last quarter. Terra Alpha Investments LLC purchased a new position in shares of Stryker during the 3rd quarter valued at approximately $1,216,000. Kepler Cheuvreux Suisse SA purchased a new position in shares of Stryker during the 3rd quarter valued at approximately $27,952,000. Finally, Daymark Wealth Partners LLC lifted its position in shares of Stryker by 436.0% during the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after buying an additional 37,307 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.60% of the stock is currently owned by corporate insiders.

Stryker Trading Up 1.5%

Shares of SYK stock opened at $317.81 on Wednesday. The stock’s fifty day moving average is $327.61 and its two-hundred day moving average is $350.70. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a market capitalization of $121.84 billion, a P/E ratio of 36.78, a PEG ratio of 1.97 and a beta of 0.80. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SYK. JPMorgan Chase & Co. decreased their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Barclays decreased their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price on the stock. in a research report on Monday, January 26th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Truist Financial reiterated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.